Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RGNX |
---|---|---|
02:26 ET | 1852 | 12.54 |
02:27 ET | 300 | 12.55 |
02:31 ET | 100 | 12.55 |
02:33 ET | 200 | 12.525 |
02:36 ET | 300 | 12.51 |
02:38 ET | 100 | 12.51 |
02:40 ET | 400 | 12.51 |
02:42 ET | 1500 | 12.55 |
02:44 ET | 967 | 12.515 |
02:47 ET | 204 | 12.5143 |
02:49 ET | 100 | 12.52 |
02:51 ET | 1600 | 12.52 |
02:54 ET | 1065 | 12.52 |
02:56 ET | 400 | 12.53 |
03:02 ET | 1153 | 12.55 |
03:03 ET | 300 | 12.57 |
03:05 ET | 4582 | 12.575 |
03:07 ET | 300 | 12.54 |
03:12 ET | 200 | 12.545 |
03:14 ET | 2100 | 12.57 |
03:16 ET | 300 | 12.58 |
03:18 ET | 200 | 12.58 |
03:20 ET | 1181 | 12.56 |
03:21 ET | 200 | 12.58 |
03:23 ET | 1011 | 12.575 |
03:25 ET | 100 | 12.58 |
03:30 ET | 1705 | 12.56 |
03:32 ET | 400 | 12.55 |
03:36 ET | 300 | 12.55 |
03:38 ET | 209 | 12.54 |
03:39 ET | 1805 | 12.53 |
03:41 ET | 3495 | 12.52 |
03:43 ET | 809 | 12.52 |
03:45 ET | 1301 | 12.52 |
03:48 ET | 2161 | 12.52 |
03:50 ET | 6117 | 12.58 |
03:52 ET | 1359 | 12.62 |
03:54 ET | 673 | 12.64 |
03:56 ET | 5072 | 12.58 |
03:57 ET | 3772 | 12.595 |
03:59 ET | 11912 | 12.58 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Regenxbio Inc | 654.1M | -2.1x | --- |
Grail Inc | 615.4M | -0.3x | --- |
Urogen Pharma Ltd | 695.4M | -4.7x | --- |
SAGE Therapeutics Inc | 731.2M | -1.5x | --- |
Alector Inc | 561.9M | -4.2x | --- |
Y-mAbs Therapeutics Inc | 552.0M | -23.4x | --- |
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $654.1M |
---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.